(NewsNation) — A new study has pitted Wegovy and Zepbound head-to-head in their ability to treat obesity.

Published in The New England Journal of Medicine on May 11, the study attempted to analyze the comparative efficacy of semaglutide (Wegovy) and tirzepatide (Zepbound) to see which drug showed better weight-loss results.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

Clinical trial participants who took Zepbound lost an average of 50 pounds over 72 weeks, while those who took Wegovy lost about 33 pounds.

Both drugs are part of a new class of medications that work by mimicking hormones in the gut and brain that regulate appetite and feelings of fullness.

But tirzepatide targets two such hormones, known as G

See Full Page